Tanshinone IIA reverses gefitinib resistance in EGFR-mutant lung cancer via inhibition of SREBP1-mediated lipogenesis.

Lei ZhangChuncao XuJunyuan HuangShiqin JiangZhiyan QinLin CaoGuoyao TanZhongxiang ZhaoMin HuangJing Jin

Published in: Phytotherapy research : PTR (2024)

Tan IIA improved gefitinib sensitivity via SREBP1-mediated lipogenesis. Tan IIA could be a potential candidate to enhance sensitivity for gefitinib-resistant NSCLC patients.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
ejection fraction
advanced non small cell lung cancer
newly diagnosed
tyrosine kinase
brain metastases
prognostic factors
type diabetes
metabolic syndrome
risk assessment
skeletal muscle
climate change